Organic Letters
Letter
Synthetic racemates 1−3 were successfully separated by
HPLC using a CHIRALPAK AD-H column to obtain the
optically pure enantiomers.
The synthetic racemic mixtures of cnidimonins A−C as well
as their enantiomers were tested for antiviral (HSV-1) activity
ORCID
Notes
(see Table 1). Each enantiomer was obtained with enantio-
The authors declare no competing financial interest.
Table 1. Antiviral Activity against HSV-1 and Cytotoxicity of
Compounds in Vero Cells
ACKNOWLEDGMENTS
■
a
This work was supported by grants from the CAMS Innovation
Fund for Medical Science (CIFMS: 2016-I2M-1-010) and the
National Natural Science Foundation of China (No.
1573321). We are grateful to the Department of Instrumental
Analysis of Peking Union Medical College for the spectroscopic
measurements.
b
c
compd
TC50 (μM)
IC50 (μM)
SI
(
(
(
(
(
(
(
(
(
±)-1
+)-1
−)-1
±)-2
+)-2
−)-2
±)-3
+)-3
−)-3
2.14
19.25
16.02
23.11
23.11
23.11
100
1.23
6.41
1.7
3.0
4.3
8
3.70
>11.11
11.11
>11.11
>33.33
>33.33
>100
REFERENCES
■
2.1
(
1) Shin, E.; Lee, C.; Sung, S. H.; Kim, Y. C.; Hwang, B. Y.; Lee, M.
K. J. Nat. Med. 2011, 65, 370−374.
>100
>100
>100
(
2
(
2) Chen, Y.; Zhang, G.; Yu, Z. J. Shenyang Pharm. Univ. 2006, 23,
56−260.
3) Wang, T.; Zhang, J. C.; Yang, M. S.; Xiao, P. G. China J. Chin.
d
acyclovir
0.41
>243.9
a
b
c
Data represent mean values for three independent determinations.
Mater. Med. 2006, 31, 718−722.
Cytotoxic concentration required to inhibit Vero cell growth by 50%.
(4) Zhou, Z. W.; Liu, P. X. China J. Chin. Mater. Med. 2005, 30,
1309−1313.
d
Selectivity index value equaled TC /IC ; Positive control.
50
50
(
5) Zhao, J. Y.; Zhou, M.; Liu, Y.; Zhang, G. L.; Luo, Y. G. Fitoterapia
2
(
011, 82, 767−771.
meric excess (ee) ≥99%. Acyclovir was used as the positive
control, with IC50 values of 0.41 μM. The racemic mixture
6) Li, C. Y.; Wu, T.; Li, Q. N.; Liang, N. C.; Huang, L. F.; Cui, L.;
Zhuang, H. Q.; Cai, C.; Mo, L. E. Chung Kuo Yao Li Hsueh Pao. 1997,
18, 286−288.
(
±)-1 possessed strong activity against HSV-1 with IC values
50
of 1.23 μM. The pure enantiomers, (+)-1 and (−)-1, exhibited
weaker activity against HSV-1 (IC : 6.41, 3.70 μM,
(7) Xie, H.; Li, Q. N.; Huang, L. F.; Wu, T. Chung Kuo Yao Li Hsueh
Pao. 1994, 15, 371−374.
5
0
respectively) than their corresponding racemic mixture (±)-1.
+)-2 showed moderate activity, with IC values of 11.11 μM.
(8) Yang, L. L.; Wang, M. C.; Chen, L. G.; Wang, C. C. Planta Med.
2
(
003, 69, 1091−1095.
9) Huang, R. L.; Chen, C. C.; Huang, Y. L.; Hsieh, D. J.; Hu, C. P.;
Chen, C. F.; Chang, C. Hepatology 1996, 24, 508−515.
10) Shi, Y.; Zhang, B.; Chen, X. J.; Xu, D. Q.; Wang, Y. X.; Dong, H.
Y.; Ma, S. R.; Sun, R. H.; Hui, Y. P.; Li, Z. C. Eur. J. Pharm. Sci. 2013,
8, 819−824.
11) Liang, H. J.; Suk, F. M.; Wang, C. K.; Hung, L. F.; Liu, D. Z.;
(
5
0
The bioassay data indicated that synergistic effects between
(
+)-1 and (−)-1 against HSV-1 may exist.
(
In this contribution, cnidimonins A−C represent a new
carbon skeleton formed through unique hybrid-dimerization
patterns of coumarin with structurally diverse units (flavonol,
benzofuran, and chromone) via an unprecedented terminal
chiral carbon of prenyl. To investigate their bioactivity in depth,
the synthesis of cnidimonins A−C was efficiently achieved.
Coupling two different moieties through convergent synthesis
was used as the key step to construct dimers. Remarkably, the
racemic mixture, (±)-1, showed stronger antiviral activity than
the corresponding pure enantiomers, suggesting that a
synergistic effect occurred, which might give some insight
into new lead ligands for the development of antiviral drugs.
Meanwhile, further investigations such as the synthesis of
analogues with more potent bioactivity and in depth biological
testing, are still required.
4
(
Chen, N. Q.; Chen, Y. C.; Chang, C. C.; Liang, Y. C. Chem.-Biol.
Interact. 2009, 181, 309−315.
(12) Hung, C. M.; Kuo, D. H.; Chou, C. H.; Su, Y. C.; Ho, C. T.;
Way, T. D. J. Agric. Food Chem. 2011, 59, 9683−9690.
(
13) Cai, J. N.; Basnet, P.; Wang, Z. T.; Komatsu, K.; Xu, L. S.; Tani,
T. J. Nat. Prod. 2000, 63, 485−488.
14) Li, F.; Awale, S.; Tezuka, Y.; Esumi, H.; Kadota, S. J. Nat. Prod.
010, 73, 623−627.
15) Franke, K.; Porzel, A.; Schmidt, J. Phytochemistry 2002, 61,
73−878.
16) Baba, K.; Kawanishi, H.; Taniguchi, M.; Kozawa, M.
(
2
(
8
(
Phytochemistry 1992, 31, 1367−1370.
̈
(17) Zhao, N.; Ren, X. D.; Ren, J. H.; Lu, H. N.; Ma, S. G.; Gao, R.
M. Org. Lett. 2015, 17, 3118−3121.
ASSOCIATED CONTENT
Supporting Information
(18) Lindsey, C. C.; Gomez-Diaz, C.; Villalba, J. M.; Pettus, T. R. R.
■
Tetrahedron 2002, 58, 4559−4565.
(
*
S
19) Zubia, E.; Luis, F. R.; Massanet, G. M.; Collado, I. G.
Tetrahedron 1992, 48, 4239−4246.
20) Lee, Y. R.; Li, Xin; Kim, J. H. J. Org. Chem. 2008, 73, 4313−
4316.
(
(
21) Morita, H.; Tomizawa, Y.; Deguchi, J. Bioorg. Med. Chem. 2009,
Detailed experimental procedures; 1D and 2D NMR,
MS, and IR spectra for novel compounds (PDF)
1
(
7, 8234−8240.
22) Herath, H. M. T. B.; Mu
̈
ller, K.; Diyabalanage, H. V. K. J.
Heterocycl. Chem. 2004, 41, 23−28.
AUTHOR INFORMATION
■
D
Org. Lett. XXXX, XXX, XXX−XXX